Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Titans Of Pharma 2024

How do big pharma CEO compensation packages stack up against company performance? 

Read More

Featured Stories


Hudson Holds Reins As Sanofi Makes Strides To Become R&D Powerhouse

“For 20 or 30 years, we were not seen as a scientific leader,” the French major’s CEO tells Scrip. Now, things have started to change with several positive readouts coming out of its immunology portfolio.

Leadership Business Strategies Clinical Trials

Bravo At Last For GSK As MATINEE Succeeds In COPD

Nucala finally succeeds in a COPD Phase III study by narrowing its target patients, setting it up to compete in a huge new market to be led by Sanofi’s Dupixent.

Clinical Trials Companies Respiratory

Travere Set For Big Expansion As Filspari Wins Full Approval In IgAN

The drug maker could end up doubling the addressable patient population for Filspari thanks to the new label removing the proteinuria threshold, plus a draft treatment guideline from a kidney disease group.

Approvals Market Access Metabolic Disorders

Asia Spotlight

Cipla Scion Back, Vice-Chair Stepping Down

Kamil Hamied, son of Cipla’s outgoing vice-chair M K Hamied, is set to re-join the company as non-executive director, following his "entrepreneurial journey." Does it signal a shift in the promoter group’s immediate considerations amid past stake sale speculation or mark routine top-level executive changes?


Commercial India

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Finance Watch: Summer Ends, But Fundraising Heats Up For ArsenalBio, Vaxcyte

ArsenalBio closed one of the largest VC rounds so far in 2024, raising $325m in series C funding, while Vaxcyte grossed $1.3bn in a follow-on offering. Also, Circle Pharma closed a $90m series D round and Jazz priced an $850m note sale, but IN8bio revealed a prioritization plan and job cuts.

Finance Watch Financing

Executives On The Move: Four New CEOs And Three New CFOs Among This Week's Changes

Recent moves in the industry include C-suite shuffle at Quantum Biopharma, Affimed and GH Research, plus Belite Bio and Dyne Therapeutics get new chief medical officers.

Leadership Executive Changes

Cipla Scion Back, Vice-Chair Stepping Down

Kamil Hamied, son of Cipla’s outgoing vice-chair M K Hamied, is set to re-join the company as non-executive director, following his "entrepreneurial journey." Does it signal a shift in the promoter group’s immediate considerations amid past stake sale speculation or mark routine top-level executive changes?

Commercial India

Stock Watch: Do Regeneron And BridgeBio Stock Movements Signal Smarter Investors?

Historically, announcements from biotech companies have triggered stock price fluctuations as investors misinterpret the details. However, two recent instances suggest this pattern might be shifting.

Stock Watch Complete Response Letters
Interviews

AstraZeneca Believes Size Matters In Amyloidosis

Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.

Clinical Trials Cardiovascular

AstraZeneca Looks To Clinical Trial Innovations To Help Meet Oncology Ambitions

The company has created a single end-to-end cancer R&D organization to help it meet its ambitious oncology goals. Its chief medical officer Cristian Massacesi talks to Scrip about how developments in conducting clinical trials will help.

Companies Clinical Trials

Strong HERCULES Data Keep Sanofi's MS Plans Alive

Tolebrutinib has missed its goal in the GEMINI 1 and 2 trials of reducing annualised relapse rate in multiple sclerosis patients but the Paris-headquartered firm is claiming a resounding victory for the BTK inhibitor in delaying disability progression in people with non-relapsing secondary progressive MS in the HERCULES study.

Neurology Clinical Trials

GenAI Reality In Pharma Amid Hype, Advances In LLMs For Therapeutics

Indegene’s CTO talks to Scrip about the state of GenAI implementations in pharma amid hype and limited clarity on ROI, the need to address foundational issues early on, promising pilots, the firm’s alliance with Microsoft and Google’s generalist LLM for therapeutics.

Commercial Artificial Intelligence
See All
Graphics

Progress Or Hype? A Decade Of Cell Therapy In Japan

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Japan Policy

Obesity Rules Large-Cap Stocks In First Half Of 2024

Lilly and Novo Nordisk were top performers among large-cap pharma stocks, while the stock prices of Bristol Myers and Gilead declined the most.

Business Strategies Companies

The IPO Queue Fills Up, But A Recovery Is A Way Off

Six biopharma companies have filed to list their shares on US exchanges so far this year, but the sums they are seeking are small.

Financing Commercial

Deal Volume Up, Value Down During The First Half

Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.

Deals M & A
See All
Recent Stories

Finance Watch: Summer Ends, But Fundraising Heats Up For ArsenalBio, Vaxcyte

ArsenalBio closed one of the largest VC rounds so far in 2024, raising $325m in series C funding, while Vaxcyte grossed $1.3bn in a follow-on offering. Also, Circle Pharma closed a $90m series D round and Jazz priced an $850m note sale, but IN8bio revealed a prioritization plan and job cuts.

Finance Watch Financing

Pharvaris Seeks To Offer New Standard Of Care In HAE

A Phase III trial with oral deucrictibant is underway for treatment of acute hereditary angioedema attacks, while the Swiss firm will begin a Phase III trial in prophylaxis later this year.

Clinical Trials Business Strategies

Chinese Cell And Gene Therapies Enjoy Limelight Amid Summer Fundraising Lull

CorrectSequence led the pack of Chinese cell and gene therapy developers seeking new funding with a roughly $14m series A-plus round. In other modalities, antibody-focused developers Mabgeek and Novamab closed series Bs.

China Financing

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on major topics facing the biopharma sector in the region and more widely.

Commercial Artificial Intelligence

HAYA To Complement Lilly’s Metabolic Disease Efforts With Long Non-Coding RNA

HAYA, a pioneer in lncRNA, is teaming up with Lilly to discover novel targets and programmable RNA therapies for obesity and metabolic disorders.

Deals Business Strategies

Lilly Inches Closer To Full Regulatory Package For Weekly Insulin

The company announced data for a fixed-dose version of insulin efsitora as well as in patients switching from basal insulin, even as it prepares to present two other Phase III studies at EASD.

Clinical Trials Business Strategies

BioMarin's Agenda Includes $4bn In Sales And Business Development

The company laid out a growth strategy to investors centered on three business units, $4bn in revenue by 2027 and $500m in cost savings. 

Sales & Earnings Business Strategies

AstraZeneca Believes Size Matters In Amyloidosis

Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.

Clinical Trials Cardiovascular

Ocaliva Exit Could Help Ipsen And Gilead’s New Cholangitis Entrants

The FXR agonist drug is facing market removal in the EU and possibly the US, which could open the door for two new PPAR agonist therapies.

Approvals Companies

Executives On The Move: Four New CEOs And Three New CFOs Among This Week's Changes

Recent moves in the industry include C-suite shuffle at Quantum Biopharma, Affimed and GH Research, plus Belite Bio and Dyne Therapeutics get new chief medical officers.

Leadership Executive Changes

Athira’s Fosgonimeton Fails In Phase II/III LIFT-AD Trial, Future Uncertain

The company said that while its drug did not achieve statistical significance on any endpoints in the Alzheimer’s study, improvements favoring fosgonimeton showed potential for HGF modulation.

Clinical Trials Neurology

Biogen’s Higher-Dose Spinraza Shows Better Efficacy, But Franchise Stands To Lose Market Share

The higher-dose version of Biogen’s SMA drug showed better efficacy than the approved 12mg dose, which could help it maintain a market foothold, but competitors are likely to overtake it.

Clinical Trials Neurology
UsernamePublicRestriction

Register